Pharmafile Logo
Pharmafocus logo
Advanced Search

tourette’s

Showing 3 posts of 3 posts found.

francesa

Teva’s Austedo fails in two paediatric Tourette’s syndrome trials

February 21, 2020
Medical Communications, Research and Development Austedo, Teva, pharma, tourette's

Israeli firm Teva has shared disappointing results for its vesicular monoamine transporter 2 (VMAT2) Austedo (deutetrabenazine) after it failed to …

News

Lundbeck acquire Abide Therapeutics in deal worth $400 million

May 7, 2019
Manufacturing and Production, Sales and Marketing Abide Therapeutics, Lundbeck, endocannabinoid system, neuropathic pain, tourette's

Danish firm Lundbeck has agreed to acquire San Diego-based biotech Abide Therapeutics as part of a deal worth $400 million. …

News
shutterstock_212432119

Neurocrine’s Ingrezza flops in Tourette’s for second time

May 25, 2017
Research and Development, Sales and Marketing Neurocrine Biosciences, tourette's

Neurocrine’s Tourette’s therapy Ingrezza (valbenazine) has been hit with yet another setback, flopping in a Phase 2 trial of paediatric …

News

Latest content

Beckman Coulter Life Sciences and Watchmaker Genomics enter collaboration

May 1, 2024

Veru announces first patients enrolled in phase 2b trial for weight loss treatment

May 1, 2024

Bayer and Evotec to collaborate on precision cardiology

April 30, 2024

PeptiDream and Novartis extend peptide discovery collaboration

April 30, 2024

Pfizer’s Beqvez approved by FDA for haemophilia B treatment

April 29, 2024